Cognia

Cognoa is a pediatric behavioral health company focused on developing digital diagnostics and therapeutics to enable earlier intervention for developmental conditions. The company's flagship product, Canvas Dx, is the first FDA-cleared diagnosis aid for autism spectrum disorder (ASD) designed for use in primary care settings. By utilizing artificial intelligence and machine learning to analyze behavioral data provided by parents and physicians, Cognoa aims to reduce the average age of diagnosis and improve long-term outcomes for children. Their development pipeline extends to digital tools for ADHD and childhood anxiety, positioning the company as a leader in the digital biocognitive space.